<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292460</url>
  </required_header>
  <id_info>
    <org_study_id>201050</org_study_id>
    <nct_id>NCT01292460</nct_id>
  </id_info>
  <brief_title>Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies</brief_title>
  <official_title>A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those Given Individually in Patients With Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Oy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Oy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of the preservative-free
      fixed tafluprost-timolol combination to those of tafluprost and timolol alone. This study
      will enroll patients who have ocular hypertension or glaucoma and who are using timolol or
      prostaglandin.

      The study medication period is 6 months, but the primary evaluation of efficacy is done at 3
      months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the average diurnal Intraocular Pressure (IOP) at 3 months</measure>
    <time_frame>At 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average diurnal IOP</measure>
    <time_frame>At 2 and 6 weeks and 6 months</time_frame>
    <description>Change from baseline in the average diurnal IOP at 2 weeks, 6 weeks and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in timewise IOPs</measure>
    <time_frame>At 2 weeks, 6 weeks, 3 months and 6 months</time_frame>
    <description>Change from baseline in timewise IOPs (at 8:00, 10:00, 16:00, 20:00)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Preservative-free timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Preservative-free FDC and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Preservative-free tafluprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Preservative-free FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol/ FDC/ Placebo/ Tafluprost</intervention_name>
    <description>Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).
Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).</description>
    <arm_group_label>Preservative-free timolol</arm_group_label>
    <arm_group_label>Preservative-free FDC and placebo</arm_group_label>
    <arm_group_label>Preservative-free tafluprost</arm_group_label>
    <arm_group_label>Preservative-free FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or more

          -  A diagnosis of ocular hypertension or open-angle glaucoma and prior use of timolol or
             prostaglandin.

          -  Meet specific IOP level at visit 1 (screening), visit 2 (run-in) and visit 3
             (baseline).

          -  Meet specific visual acuity score

          -  Are willing to follow instructions

          -  Have provided a written informed consent

        Exclusion Criteria:

          -  Females who are pregnant, nursing or planning pregnancy

          -  IOP of 35 mmHg or greater

          -  Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or
             pigmentary glaucoma in either eye

          -  Suspected contraindication or hypersensitivity to study medications tafluprost or
             timolol (e.g. asthma, low pulse)or to wash-out medication brinzolamide

          -  Glaucoma filtration surgery or any other ocular surgery (including ocular laser
             procedures) within 6 months prior to Screening

          -  Use of contact lenses at Screening or during the study

          -  Presence of any abnormality or significant illness that could be expected to interfere
             with the patient safety or study parameters

          -  Current participation in another clinical trial within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Auli Ropo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Santen Oy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hannu Uusitalo, M.D., Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tampere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye clinic, University Hospital of Kuopio</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Clinic, University Hospital of Oulu</name>
      <address>
        <city>Oulu</city>
        <zip>90029 OYS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

